19-05-2025
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), Waters (WAT) and Cingulate Inc (CING)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Axsome Therapeutics (AXSM – Research Report), Waters (WAT – Research Report) and Cingulate Inc (CING – Research Report).
Confident Investing Starts Here:
Axsome Therapeutics (AXSM)
In a report issued on May 16, Vikram Purohit from Morgan Stanley maintained a Buy rating on Axsome Therapeutics, with a price target of $190.00. The company's shares closed last Friday at $107.53.
According to Purohit 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.5% and a 30.9% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, BioMarin Pharmaceutical, and Arcutis Biotherapeutics.
Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $177.85, a 66.6% upside from current levels. In a report issued on May 1, Mizuho Securities also maintained a Buy rating on the stock with a $210.00 price target.
Waters (WAT)
Bank of America Securities analyst Michael Ryskin reiterated a Hold rating on Waters yesterday and set a price target of $370.00. The company's shares closed last Friday at $359.48.
According to Ryskin is a 2-star analyst with an average return of 0.2% and a 45.0% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, West Pharmaceutical Services, and Fortrea Holdings Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Waters with a $393.77 average price target, representing an 11.9% upside. In a report issued on May 6, TD Cowen also maintained a Hold rating on the stock with a $375.00 price target.
Cingulate Inc (CING)
In a report released yesterday, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Cingulate Inc, with a price target of $11.00. The company's shares closed last Friday at $3.82, close to its 52-week low of $1.80.
According to Pachaiyappan has 0 stars on 0-5 stars ranking scale with an average return of -9.8% and a 31.5% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Entrada Therapeutics Inc, and Gain Therapeutics.
